Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI

What Was Tested

This registered phase 2, phase 3 trial tested Cetrorelix.

It had two arms (groups): Dydrogestrone (experimental) and GnRH antagonist (active comparator).

The registry classes the interventions as drug.

More on the Plan

Each patient will be subjected to: Full history taking.

Systematic clinical examination to assess the general condition, body mass index (BMI) and local pelvic physical findings and AFC by trans-vaginal ultrasound on D2 to 3 of menstruation.

Routine labs as CBC, liver \& kidney functions to exclude general disease as a contraindication for induction or pregnancy.

Blood sample will be obtained for assessment of basal serum levels of FSH, LH, E2 on days 2- 3 of the cycle.

Who Took Part

200 actual participants took part.

It was open to women only aged from 20 years up to 40 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Undergoing trial of ICSI. BMI ≤ 30. AFC ≥ 20.

The full record lists 4 inclusion and 6 exclusion criteria; among the exclusions: any known contraindications to the approved fertility drugs; severe endometriosis; uterine malformations or abnormal uterine cavity.

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Random assignment meant chance, not the researchers, decided who got Cetrorelix and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Being open-label, the Cetrorelix study did not mask who received what.

It started in 2024-01-01 with completion listed for 2026-03-30.

It ran at 1 site in Egypt.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: oocytes retrieved (time frame: 1 month of induction for ICSI trial).

It also tracked 2 secondary outcomes, for example Duration of stimulation days and chemical pregnancy rate.

What This Means in Plain Language

Put simply, this is a phase 2, phase 3, randomized trial of Cetrorelix in 200 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Cetrorelix compound page, all human trials.